世界のクロストリジウムディフィシル分子診断市場インサイト及び予測(感度90%以上、感度90%以下)

◆英語タイトル:Global Molecular Diagnosis of Clostridium Difficile Market Insights, Forecast to 2028

QYResearchが発行した調査報告書(QY22JLX09843)◆商品コード:QY22JLX09843
◆発行会社(リサーチ会社):QYResearch
◆発行日:2022年7月(※2025年版があります。お問い合わせください。)
◆ページ数:106
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:医療機器
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥744,800見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,117,200見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,489,600見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

COVID-19のパンデミックにより、クロストリジウムディフィシル分子診断のグローバル市場規模は2022年にUS$xxxと推定され、調査期間中のCAGRはxxx%で、2028年までに再調整された規模はUS$xxxになると予測されています。この医療危機による経済変化を十分に考慮すると、2021年にクロストリジウムディフィシル分子診断の世界市場のxxx%を占める「感度90%以上」タイプは、2028年までにUS$xxxの規模になり、パンデミック後の修正xxx%CAGRで成長すると予測されています。一方、「病院」セグメントは、この予測期間を通じてxxx%のCAGRに変更されます。
クロストリジウムディフィシル分子診断の中国市場規模は2021年にUS$xxxと分析されており、米国とヨーロッパの市場規模はそれぞれUS$xxxとUS$xxxです。米国の割合は2021年にxxx%であり、中国とヨーロッパはそれぞれxxx%とxxx%です。中国の割合は2028年にxxx%に達し、対象期間を通じてxxx%のCAGRを記録すると予測されています。日本、韓国、東南アジアはアジアで注目市場であり、今後6年間のCAGRはそれぞれxxx%、xxx%、xxx%になる見通しです。ヨーロッパのクロストリジウムディフィシル分子診断市場については、ドイツは2028年までにUS$xxxに達すると予測されており、予測期間中のCAGRはxxx%になる見通しです。

クロストリジウムディフィシル分子診断のグローバル主要企業には、Roche、Thermo Scientific、Cepheid (Danaher)、BD、Meridian、TECHLAB、Luminex、CerTest Biotec、Quidel、Zhejiang Orient Gene Biotech、Beijing Promed Medical Technology、Jiangsu Besthree Biotechnologyなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

クロストリジウムディフィシル分子診断市場は、種類と用途によって区分されます。世界のクロストリジウムディフィシル分子診断市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別および用途別の販売量、売上、予測に焦点を当てています。

【種類別セグメント】
感度90%以上、感度90%以下

【用途別セグメント】
病院、診療所、実験室、在宅介護、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- クロストリジウムディフィシル分子診断製品概要
- 種類別市場(感度90%以上、感度90%以下)
- 用途別市場(病院、診療所、実験室、在宅介護、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界のクロストリジウムディフィシル分子診断販売量予測2017-2028
- 世界のクロストリジウムディフィシル分子診断売上予測2017-2028
- クロストリジウムディフィシル分子診断の地域別販売量
- クロストリジウムディフィシル分子診断の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別クロストリジウムディフィシル分子診断販売量
- 主要メーカー別クロストリジウムディフィシル分子診断売上
- 主要メーカー別クロストリジウムディフィシル分子診断価格
- 競争状況の分析
- 企業M&A動向
・種類別市場規模(感度90%以上、感度90%以下)
- クロストリジウムディフィシル分子診断の種類別販売量
- クロストリジウムディフィシル分子診断の種類別売上
- クロストリジウムディフィシル分子診断の種類別価格
・用途別市場規模(病院、診療所、実験室、在宅介護、その他)
- クロストリジウムディフィシル分子診断の用途別販売量
- クロストリジウムディフィシル分子診断の用途別売上
- クロストリジウムディフィシル分子診断の用途別価格
・北米市場
- 北米のクロストリジウムディフィシル分子診断市場規模(種類別、用途別)
- 主要国別のクロストリジウムディフィシル分子診断市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパのクロストリジウムディフィシル分子診断市場規模(種類別、用途別)
- 主要国別のクロストリジウムディフィシル分子診断市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋のクロストリジウムディフィシル分子診断市場規模(種類別、用途別)
- 主要国別のクロストリジウムディフィシル分子診断市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米のクロストリジウムディフィシル分子診断市場規模(種類別、用途別)
- 主要国別のクロストリジウムディフィシル分子診断市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカのクロストリジウムディフィシル分子診断市場規模(種類別、用途別)
- 主要国別のクロストリジウムディフィシル分子診断市場規模(トルコ、サウジアラビア)
・企業情報
Roche、Thermo Scientific、Cepheid (Danaher)、BD、Meridian、TECHLAB、Luminex、CerTest Biotec、Quidel、Zhejiang Orient Gene Biotech、Beijing Promed Medical Technology、Jiangsu Besthree Biotechnology
・産業チェーン及び販売チャネル分析
- クロストリジウムディフィシル分子診断の産業チェーン分析
- クロストリジウムディフィシル分子診断の原材料
- クロストリジウムディフィシル分子診断の生産プロセス
- クロストリジウムディフィシル分子診断の販売及びマーケティング
- クロストリジウムディフィシル分子診断の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- クロストリジウムディフィシル分子診断の産業動向
- クロストリジウムディフィシル分子診断のマーケットドライバー
- クロストリジウムディフィシル分子診断の課題
- クロストリジウムディフィシル分子診断の阻害要因
・主な調査結果

Clostridium difficile infection (CDI) is one of the most important causes of nosocomial diarrhoea and is also becoming important in the community and in populations with low or no risk factors.Especially during outbreaks and during the spread of strains with increased virulence it is important that the laboratory diagnosis is rapid and sensitive to ensure appropriate therapy and quick implementation of hospital hygiene measures.Therefore, the improvement of diagnostic methods is becoming more and more important.
Market Analysis and Insights: Global Molecular Diagnosis of Clostridium Difficile Market
Due to the COVID-19 pandemic, the global Molecular Diagnosis of Clostridium Difficile market size is estimated to be worth US$ million in 2022 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, Sensitivity Above 90% accounting for % of the Molecular Diagnosis of Clostridium Difficile global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospital segment is altered to an % CAGR throughout this forecast period.
China Molecular Diagnosis of Clostridium Difficile market size is valued at US$ million in 2021, while the US and Europe Molecular Diagnosis of Clostridium Difficile are US$ million and US$ million, severally. The proportion of the US is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Molecular Diagnosis of Clostridium Difficile landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
The global key manufacturers of Molecular Diagnosis of Clostridium Difficile include Roche, Thermo Scientific, Cepheid (Danaher), BD, Meridian, TECHLAB, Luminex, CerTest Biotec and Quidel, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
Global Molecular Diagnosis of Clostridium Difficile Scope and Segment
Molecular Diagnosis of Clostridium Difficile market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Molecular Diagnosis of Clostridium Difficile market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Sensitivity Above 90%
Sensitivity Below 90%
Segment by Application
Hospital
Clinic
Laboratory
Home Care
Others
By Company
Roche
Thermo Scientific
Cepheid (Danaher)
BD
Meridian
TECHLAB
Luminex
CerTest Biotec
Quidel
Zhejiang Orient Gene Biotech
Beijing Promed Medical Technology
Jiangsu Besthree Biotechnology
By Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

❖ レポートの目次 ❖

1 Study Coverage
1.1 Molecular Diagnosis of Clostridium Difficile Product Introduction
1.2 Market by Type
1.2.1 Global Molecular Diagnosis of Clostridium Difficile Market Size Growth Rate by Type, 2017 VS 2021 VS 2028
1.2.2 Sensitivity Above 90%
1.2.3 Sensitivity Below 90%
1.3 Market by Application
1.3.1 Global Molecular Diagnosis of Clostridium Difficile Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Laboratory
1.3.5 Home Care
1.3.6 Others
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Molecular Diagnosis of Clostridium Difficile Sales Estimates and Forecasts 2017-2028
2.2 Global Molecular Diagnosis of Clostridium Difficile Revenue Estimates and Forecasts 2017-2028
2.3 Global Molecular Diagnosis of Clostridium Difficile Revenue by Region: 2017 VS 2021 VS 2028
2.4 Global Molecular Diagnosis of Clostridium Difficile Sales by Region
2.4.1 Global Molecular Diagnosis of Clostridium Difficile Sales by Region (2017-2022)
2.4.2 Global Sales Molecular Diagnosis of Clostridium Difficile by Region (2023-2028)
2.5 Global Molecular Diagnosis of Clostridium Difficile Revenue by Region
2.5.1 Global Molecular Diagnosis of Clostridium Difficile Revenue by Region (2017-2022)
2.5.2 Global Molecular Diagnosis of Clostridium Difficile Revenue by Region (2023-2028)
2.6 North America
2.7 Europe
2.8 Asia-Pacific
2.9 Latin America
2.10 Middle East & Africa
3 Competition by Manufacturers
3.1 Global Molecular Diagnosis of Clostridium Difficile Sales by Manufacturers
3.1.1 Global Top Molecular Diagnosis of Clostridium Difficile Manufacturers by Sales (2017-2022)
3.1.2 Global Molecular Diagnosis of Clostridium Difficile Sales Market Share by Manufacturers (2017-2022)
3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Molecular Diagnosis of Clostridium Difficile in 2021
3.2 Global Molecular Diagnosis of Clostridium Difficile Revenue by Manufacturers
3.2.1 Global Molecular Diagnosis of Clostridium Difficile Revenue by Manufacturers (2017-2022)
3.2.2 Global Molecular Diagnosis of Clostridium Difficile Revenue Market Share by Manufacturers (2017-2022)
3.2.3 Global Top 10 and Top 5 Companies by Molecular Diagnosis of Clostridium Difficile Revenue in 2021
3.3 Global Molecular Diagnosis of Clostridium Difficile Sales Price by Manufacturers (2017-2022)
3.4 Analysis of Competitive Landscape
3.4.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Molecular Diagnosis of Clostridium Difficile Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4.3 Global Molecular Diagnosis of Clostridium Difficile Manufacturers Geographical Distribution
3.5 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
4.1 Global Molecular Diagnosis of Clostridium Difficile Sales by Type
4.1.1 Global Molecular Diagnosis of Clostridium Difficile Historical Sales by Type (2017-2022)
4.1.2 Global Molecular Diagnosis of Clostridium Difficile Forecasted Sales by Type (2023-2028)
4.1.3 Global Molecular Diagnosis of Clostridium Difficile Sales Market Share by Type (2017-2028)
4.2 Global Molecular Diagnosis of Clostridium Difficile Revenue by Type
4.2.1 Global Molecular Diagnosis of Clostridium Difficile Historical Revenue by Type (2017-2022)
4.2.2 Global Molecular Diagnosis of Clostridium Difficile Forecasted Revenue by Type (2023-2028)
4.2.3 Global Molecular Diagnosis of Clostridium Difficile Revenue Market Share by Type (2017-2028)
4.3 Global Molecular Diagnosis of Clostridium Difficile Price by Type
4.3.1 Global Molecular Diagnosis of Clostridium Difficile Price by Type (2017-2022)
4.3.2 Global Molecular Diagnosis of Clostridium Difficile Price Forecast by Type (2023-2028)
5 Market Size by Application
5.1 Global Molecular Diagnosis of Clostridium Difficile Sales by Application
5.1.1 Global Molecular Diagnosis of Clostridium Difficile Historical Sales by Application (2017-2022)
5.1.2 Global Molecular Diagnosis of Clostridium Difficile Forecasted Sales by Application (2023-2028)
5.1.3 Global Molecular Diagnosis of Clostridium Difficile Sales Market Share by Application (2017-2028)
5.2 Global Molecular Diagnosis of Clostridium Difficile Revenue by Application
5.2.1 Global Molecular Diagnosis of Clostridium Difficile Historical Revenue by Application (2017-2022)
5.2.2 Global Molecular Diagnosis of Clostridium Difficile Forecasted Revenue by Application (2023-2028)
5.2.3 Global Molecular Diagnosis of Clostridium Difficile Revenue Market Share by Application (2017-2028)
5.3 Global Molecular Diagnosis of Clostridium Difficile Price by Application
5.3.1 Global Molecular Diagnosis of Clostridium Difficile Price by Application (2017-2022)
5.3.2 Global Molecular Diagnosis of Clostridium Difficile Price Forecast by Application (2023-2028)
6 North America
6.1 North America Molecular Diagnosis of Clostridium Difficile Market Size by Type
6.1.1 North America Molecular Diagnosis of Clostridium Difficile Sales by Type (2017-2028)
6.1.2 North America Molecular Diagnosis of Clostridium Difficile Revenue by Type (2017-2028)
6.2 North America Molecular Diagnosis of Clostridium Difficile Market Size by Application
6.2.1 North America Molecular Diagnosis of Clostridium Difficile Sales by Application (2017-2028)
6.2.2 North America Molecular Diagnosis of Clostridium Difficile Revenue by Application (2017-2028)
6.3 North America Molecular Diagnosis of Clostridium Difficile Market Size by Country
6.3.1 North America Molecular Diagnosis of Clostridium Difficile Sales by Country (2017-2028)
6.3.2 North America Molecular Diagnosis of Clostridium Difficile Revenue by Country (2017-2028)
6.3.3 United States
6.3.4 Canada
7 Europe
7.1 Europe Molecular Diagnosis of Clostridium Difficile Market Size by Type
7.1.1 Europe Molecular Diagnosis of Clostridium Difficile Sales by Type (2017-2028)
7.1.2 Europe Molecular Diagnosis of Clostridium Difficile Revenue by Type (2017-2028)
7.2 Europe Molecular Diagnosis of Clostridium Difficile Market Size by Application
7.2.1 Europe Molecular Diagnosis of Clostridium Difficile Sales by Application (2017-2028)
7.2.2 Europe Molecular Diagnosis of Clostridium Difficile Revenue by Application (2017-2028)
7.3 Europe Molecular Diagnosis of Clostridium Difficile Market Size by Country
7.3.1 Europe Molecular Diagnosis of Clostridium Difficile Sales by Country (2017-2028)
7.3.2 Europe Molecular Diagnosis of Clostridium Difficile Revenue by Country (2017-2028)
7.3.3 Germany
7.3.4 France
7.3.5 U.K.
7.3.6 Italy
7.3.7 Russia
8 Asia Pacific
8.1 Asia Pacific Molecular Diagnosis of Clostridium Difficile Market Size by Type
8.1.1 Asia Pacific Molecular Diagnosis of Clostridium Difficile Sales by Type (2017-2028)
8.1.2 Asia Pacific Molecular Diagnosis of Clostridium Difficile Revenue by Type (2017-2028)
8.2 Asia Pacific Molecular Diagnosis of Clostridium Difficile Market Size by Application
8.2.1 Asia Pacific Molecular Diagnosis of Clostridium Difficile Sales by Application (2017-2028)
8.2.2 Asia Pacific Molecular Diagnosis of Clostridium Difficile Revenue by Application (2017-2028)
8.3 Asia Pacific Molecular Diagnosis of Clostridium Difficile Market Size by Region
8.3.1 Asia Pacific Molecular Diagnosis of Clostridium Difficile Sales by Region (2017-2028)
8.3.2 Asia Pacific Molecular Diagnosis of Clostridium Difficile Revenue by Region (2017-2028)
8.3.3 China
8.3.4 Japan
8.3.5 South Korea
8.3.6 India
8.3.7 Australia
8.3.8 China Taiwan
8.3.9 Indonesia
8.3.10 Thailand
8.3.11 Malaysia
9 Latin America
9.1 Latin America Molecular Diagnosis of Clostridium Difficile Market Size by Type
9.1.1 Latin America Molecular Diagnosis of Clostridium Difficile Sales by Type (2017-2028)
9.1.2 Latin America Molecular Diagnosis of Clostridium Difficile Revenue by Type (2017-2028)
9.2 Latin America Molecular Diagnosis of Clostridium Difficile Market Size by Application
9.2.1 Latin America Molecular Diagnosis of Clostridium Difficile Sales by Application (2017-2028)
9.2.2 Latin America Molecular Diagnosis of Clostridium Difficile Revenue by Application (2017-2028)
9.3 Latin America Molecular Diagnosis of Clostridium Difficile Market Size by Country
9.3.1 Latin America Molecular Diagnosis of Clostridium Difficile Sales by Country (2017-2028)
9.3.2 Latin America Molecular Diagnosis of Clostridium Difficile Revenue by Country (2017-2028)
9.3.3 Mexico
9.3.4 Brazil
9.3.5 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Molecular Diagnosis of Clostridium Difficile Market Size by Type
10.1.1 Middle East and Africa Molecular Diagnosis of Clostridium Difficile Sales by Type (2017-2028)
10.1.2 Middle East and Africa Molecular Diagnosis of Clostridium Difficile Revenue by Type (2017-2028)
10.2 Middle East and Africa Molecular Diagnosis of Clostridium Difficile Market Size by Application
10.2.1 Middle East and Africa Molecular Diagnosis of Clostridium Difficile Sales by Application (2017-2028)
10.2.2 Middle East and Africa Molecular Diagnosis of Clostridium Difficile Revenue by Application (2017-2028)
10.3 Middle East and Africa Molecular Diagnosis of Clostridium Difficile Market Size by Country
10.3.1 Middle East and Africa Molecular Diagnosis of Clostridium Difficile Sales by Country (2017-2028)
10.3.2 Middle East and Africa Molecular Diagnosis of Clostridium Difficile Revenue by Country (2017-2028)
10.3.3 Turkey
10.3.4 Saudi Arabia
11 Company Profiles
11.1 Roche
11.1.1 Roche Corporation Information
11.1.2 Roche Overview
11.1.3 Roche Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.1.4 Roche Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.1.5 Roche Recent Developments
11.2 Thermo Scientific
11.2.1 Thermo Scientific Corporation Information
11.2.2 Thermo Scientific Overview
11.2.3 Thermo Scientific Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.2.4 Thermo Scientific Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.2.5 Thermo Scientific Recent Developments
11.3 Cepheid (Danaher)
11.3.1 Cepheid (Danaher) Corporation Information
11.3.2 Cepheid (Danaher) Overview
11.3.3 Cepheid (Danaher) Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.3.4 Cepheid (Danaher) Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.3.5 Cepheid (Danaher) Recent Developments
11.4 BD
11.4.1 BD Corporation Information
11.4.2 BD Overview
11.4.3 BD Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.4.4 BD Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.4.5 BD Recent Developments
11.5 Meridian
11.5.1 Meridian Corporation Information
11.5.2 Meridian Overview
11.5.3 Meridian Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.5.4 Meridian Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.5.5 Meridian Recent Developments
11.6 TECHLAB
11.6.1 TECHLAB Corporation Information
11.6.2 TECHLAB Overview
11.6.3 TECHLAB Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.6.4 TECHLAB Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.6.5 TECHLAB Recent Developments
11.7 Luminex
11.7.1 Luminex Corporation Information
11.7.2 Luminex Overview
11.7.3 Luminex Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.7.4 Luminex Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.7.5 Luminex Recent Developments
11.8 CerTest Biotec
11.8.1 CerTest Biotec Corporation Information
11.8.2 CerTest Biotec Overview
11.8.3 CerTest Biotec Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.8.4 CerTest Biotec Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.8.5 CerTest Biotec Recent Developments
11.9 Quidel
11.9.1 Quidel Corporation Information
11.9.2 Quidel Overview
11.9.3 Quidel Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.9.4 Quidel Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.9.5 Quidel Recent Developments
11.10 Zhejiang Orient Gene Biotech
11.10.1 Zhejiang Orient Gene Biotech Corporation Information
11.10.2 Zhejiang Orient Gene Biotech Overview
11.10.3 Zhejiang Orient Gene Biotech Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.10.4 Zhejiang Orient Gene Biotech Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.10.5 Zhejiang Orient Gene Biotech Recent Developments
11.11 Beijing Promed Medical Technology
11.11.1 Beijing Promed Medical Technology Corporation Information
11.11.2 Beijing Promed Medical Technology Overview
11.11.3 Beijing Promed Medical Technology Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.11.4 Beijing Promed Medical Technology Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.11.5 Beijing Promed Medical Technology Recent Developments
11.12 Jiangsu Besthree Biotechnology
11.12.1 Jiangsu Besthree Biotechnology Corporation Information
11.12.2 Jiangsu Besthree Biotechnology Overview
11.12.3 Jiangsu Besthree Biotechnology Molecular Diagnosis of Clostridium Difficile Sales, Price, Revenue and Gross Margin (2017-2022)
11.12.4 Jiangsu Besthree Biotechnology Molecular Diagnosis of Clostridium Difficile Product Model Numbers, Pictures, Descriptions and Specifications
11.12.5 Jiangsu Besthree Biotechnology Recent Developments
12 Industry Chain and Sales Channels Analysis
12.1 Molecular Diagnosis of Clostridium Difficile Industry Chain Analysis
12.2 Molecular Diagnosis of Clostridium Difficile Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Molecular Diagnosis of Clostridium Difficile Production Mode & Process
12.4 Molecular Diagnosis of Clostridium Difficile Sales and Marketing
12.4.1 Molecular Diagnosis of Clostridium Difficile Sales Channels
12.4.2 Molecular Diagnosis of Clostridium Difficile Distributors
12.5 Molecular Diagnosis of Clostridium Difficile Customers
13 Market Drivers, Opportunities, Challenges and Risks Factors Analysis
13.1 Molecular Diagnosis of Clostridium Difficile Industry Trends
13.2 Molecular Diagnosis of Clostridium Difficile Market Drivers
13.3 Molecular Diagnosis of Clostridium Difficile Market Challenges
13.4 Molecular Diagnosis of Clostridium Difficile Market Restraints
14 Key Findings in The Global Molecular Diagnosis of Clostridium Difficile Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界のクロストリジウムディフィシル分子診断市場インサイト及び予測(感度90%以上、感度90%以下)(Global Molecular Diagnosis of Clostridium Difficile Market Insights, Forecast to 2028)]についてメールでお問い合わせはこちらでお願いします。